Press Detail





Biotest AG: Former Biotest employee sentenced

News: Biotest AG / Key word(s): Legal Matter

2016-07-14 / 17:46
The issuer is solely responsible for the content of this announcement.


/

PRESS RELEASE

Former Biotest employee sentenced

Dreieich, 14 July 2016. Today, the Landgericht Darmstadt (District Court Darmstadt, Germany) sentenced a former Biotest representative for Russia to imprisonment of 5 years and 9 months. According to the judgement of the court, the former employee is guilty of complicity in fraud and tax evasion in the years 2007-2011. Her husband was sentenced to imprisonment of 4 years and 6 months. The sentence is not yet final. An appeal to the Bundesgerichtshof (German Federal Court of Justice) is possible. The company had dismissed the former employee in 2013. Biotest AG is not a party in these proceedings. The sentence pertains neither to Biotest AG nor to any officials of Biotest. The company will await the written grounds for the verdict and evaluate possible next steps against the accused. Biotest had restructured its sales and distribution in Russia in January 2013. The company has since been cooperating with a big German pharmaceutical company.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,300 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



2016-07-14 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this